Asset Details
Do you wish to reserve the book?
Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy
Do you wish to request the book?
Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy
2020
Overview
Cell membrane- covered drug-delivery nanoplatforms have been garnering attention because of their enhanced bio-interfacing capabilities that originate from source cells. In this top-down technique, nanoparticles (NPs) are covered by various membrane coatings, including membranes from specialized cells or hybrid membranes that combine the capacities of different types of cell membranes. Here, hybrid membrane-coated doxorubicin (Dox)-loaded poly(lactic-co-glycolic acid) (PLGA) NPs (DPLGA@[RAW-4T1] NPs) were fabricated by fusing membrane components derived from RAW264.7(RAW) and 4T1 cells (4T1). These NPs were used to treat lung metastases originating from breast cancer. This study indicates that the coupling of NPs with a hybrid membrane derived from macrophage and cancer cells has several advantages, such as the tendency to accumulate at sites of inflammation, ability to target specific metastasis, homogenous tumor targeting abilities in vitro, and markedly enhanced multi-target capability in a lung metastasis model in vivo. The DPLGA@[RAW-4T1] NPs exhibited excellent chemotherapeutic potential with approximately 88.9% anti-metastasis efficacy following treatment of breast cancer-derived lung metastases. These NPs were robust and displayed the multi-targeting abilities of hybrid membranes. This study provides a promising biomimetic nanoplatform for effective treatment of breast cancer metastasis.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Antineoplastic Agents - chemistry
/ Antineoplastic Agents - pharmacokinetics
/ Antineoplastic Agents - pharmacology
/ Antineoplastic Agents - therapeutic use
/ Biomimetic Materials - chemistry
/ Breast Neoplasms - pathology
/ Cell Proliferation - drug effects
/ Chemistry and Materials Science
/ Coatings
/ Doxorubicin - pharmacokinetics
/ Doxorubicin - therapeutic use
/ Female
/ Lung Neoplasms - drug therapy
/ Lungs
/ Mammary Neoplasms, Experimental
/ Mice
/ Nanoparticles - therapeutic use
/ Proteins
/ Tumors
